Insights
Search Results
News Articles
5.21.26
Michael Hostetler Recognized Among Daily Journal’s 2026 Top IP Lawyers
On May 21, 2026, Wilson Sonsini partner Michael Hostetler was recognized in the Daily Journal’s special report "Top Intellectual Property Lawyers 2026," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Michael has over 25 years of experience specializing in patent law for life sciences companies, particularly in pharmaceuticals and biotechnology.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Alerts
5.07.26
Federal Circuit Provides Path to Written Description and Enablement for Patents Related to Methods of Using a Well-Known Class of Molecules
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit (the court) issued a precedential decision in Teva Pharmaceuticals International GmbH v. Eli Lily and Company, determining that the claims of Teva’s U.S. Patent Nos. 8,586,045 (the ’045 patent), 9,884,907 (the ’907 patent), and 9,884,908 (the ’908 patent) (collectively, the Headache Patents) relating to methods of reducing headache by administration of humanized anti-CGRP antagonist antibodies are not invalid for lack of written description or enablement. The decision reversed a district court’s judgment as a matter of law (JMOL) decision concluding otherwise, and reinstated the jury’s findings that Eli Lilly’s Emgality® product willfully infringed the Headache Patents.
News Articles
5.07.26
Tait Graves Named Among WIPR Leaders 2026
On May 1, 2026, World Intellectual Property Review (WIPR) named Wilson Sonsini partner Charles Tait Graves to its WIPR Leaders 2026 guide, a list of the leading intellectual property attorneys globally. The guide recognizes individuals and attorneys who are leaders in their fields and shaping the future of intellectual property in the legal space.
Client Highlights
5.04.26
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises Frazier Life Sciences on IP Matters Related to Immutrin’s $87 Million Series A
On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Centessa on IP Matters Related to Acquisition by Lilly
On March 31, 2026, Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Eli Lilly and Company (Lilly), an American multinational pharmaceutical company, to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and the CVR represents an additional potential aggregate equity value of approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati advised Centessa in IP matters related to the transaction.
Client Highlights
3.30.26
Firm Advises Pinnacle Medicines on Corporate and IP Matters Related to Oversubscribed $89 Million Series B Financing
On March 26, 2026, Pinnacle Medicines, a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed. Wilson Sonsini Goodrich & Rosati advised Pinnacle on corporate and IP matters related to the transaction.
Client Highlights
3.12.26
Firm Advises Day One on IP Matters Related to $2.5 Billion Acquisition by Servier
On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.
Client Highlights
3.06.26
Firm Obtains Complete Jury Victory for Cyntec in Patent Validity Trial
On March 5, 2026, Wilson Sonsini Goodrich & Rosati secured a complete jury victory in a patent invalidity trial in the U.S. District Court for the Northern District of California on behalf of firm client Cyntec Company, Ltd. Rejecting defendant Chilisin’s arguments on obviousness, the jury found that all asserted claims of Cyntec’s U.S. Patent Nos. 8,922,312 and 9,481,037 were valid. Wilson Sonsini also represented Cyntec in a previous jury trial which had found that Chilisin willfully infringed both patents and imposed a 5 percent royalty.